DORILARGA CHIDAMLI TUBERKULYOZDA LABORATOR O‘ZGARISHLAR
Keywords:
Kirish. Dori̇ larga chidamli tuberkulyoz (DChTB) – Mycobacterium tuberculosis shtammlarining bir yoki bir nechta protivotuberkulyoz vositalarga rezistentlik bilan kechuvchi yuqumli kasallikdir. Jahon sog‘liqni saqlash tashkiloti (JSST) ma’lumotlariga ko‘ra, 2022 yilda rifampitsin va izoniazidga chidamli, ya’ni ko‘p doriga chidamli tuberkulyoz (KDChTB) holatlari 450 000 dan oshgan. Keng doriga chidamli (KDChTB) va birlamchi keng doriga chidamlilik (OKDChTB) shakllari davolash muvaffaqiyatini keskin kamaytirmoqda.Abstract
Dori̇ larga chidamli tuberkulyoz (DChTB) global sog‘liqni saqlash
muammosi bo‘lib, uning laborator ko‘rsatkichlaridagi o‘zgarishlar kasallikning
kechishi, davoga javobi va prognozini baholashda muhim ahamiyatga ega. Ushbu
maqolada DChTBda kuzatiladigan gematologik, immunologik, biofizik va
molekulyar-genetik laborator o‘zgarishlar tizimli ravishda tahlil qilinadi. Maqola
IMRAD formatida tuzilgan bo‘lib, so‘nggi 5 yil ichida nashr etilgan 12 ta ilmiy
manbaga asoslangan adabiyotlar sharhini o‘z ichiga oladi.
References
1. Adewole OO, Eze G, Akintomide AO, et al. Haematological parameter
among drug resistant tuberculosis patients in Ibadan, South-Western Nigeria. Afr
Health Sci. 2024;24(1):10-15.
2. Yitbarek GY, Ayele AG, Asrie F, et al. Hematological Profiles of
Pulmonary Tuberculosis and Multi-Drug-Resistant Tuberculosis Patients at Debre
Tabor, North-Central Ethiopia. Health Sci Rep. 2026;9(4):e72223.
3. Matsuyama T, Kubota S, Fushimi S, et al. Anemia with elevation of
growth differentiation factor-15 level in linezolid treated multidrug-resistant
tuberculosis. IDCases. 2022;29:e01591.
4. Ibnouf MA, Almahdi MA, Elhassan AM, et al. Immuno-haematological
indices in Multi-Drug resistant tuberculosis: Implications for prognosis. Sokoto J
Med Lab Sci. 2024;9(2):45-52.
5. Dookie S, Köser CU, O’Donnell M, et al. Clinical implications of
molecular drug resistance testing for Mycobacterium tuberculosis: a 2023
TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023;23(4):e122-e137.
6. Sharma D, Bisht D, Khan AU. Challenges & Solutions for Recent
Advancements in Multi-Drugs Resistance Tuberculosis: A Review. Microbiol
Insights. 2023;16:11786361231152438.
7. Chand M, Vaz M, Gupta P, et al. Speeding up drug susceptibility testing
in Mycobacterium tuberculosis using RNA biomarkers. EBioMedicine.
2025;113:105611.
8. Sharma S, Gupta R, Singh A, et al. Prognostic Value of Time-to-Positivity
and Cycle Threshold Values in Predicting Tuberculosis Outcomes and Multidrug
Resistance in Northern India. Cureus. 2025;17(6):e86087.
